Strict Standards: Only variables should be assigned by reference in /opt/lampp/htdocs/dokuwiki/inc/JpegMeta.php on line 2331

Strict Standards: Only variables should be assigned by reference in /opt/lampp/htdocs/dokuwiki/inc/JpegMeta.php on line 2331

Today's Alert 2021

Today's Alert presents national and international news and events related to science and technology advancements in the CGI subject interests,
and especially reports that marked the outstanding academic performance of CGI.
From April 2019, Today's Alert combines news which formerly disseminated in CGI Learning Center Bulletin-Quarterly.
You can also view Today's Alert from

June 2021

The Sinovac COVID-19 vaccine: What you need to know

Posted by Juthatip


Who should be vaccinated first?

While COVID-19 vaccine supplies are limited, health workers at high risk of exposure and older people should be prioritised for vaccination.
Countries can refer to the WHO Prioritization Roadmap and the WHO Values Framework as guidance for their prioritisation of target groups.
The vaccine is not recommended for persons younger than 18 years of age, pending the results of further studied in that age group.

Who is the vaccine not recommended for?

Individuals with a history of anaphylaxis to any component of the vaccine should not take it.
Persons with acute PCR-confirmed COVID-19 should not be vaccinated until after they have recovered from acute illness and the criteria for ending isolation have been met.
Anyone with a body temperature over 38.5°C should postpone vaccination until they no longer have a fever.

What is the recommended dosage?

SAGE recommends the use of Sinovac-CoronaVac vaccine as 2 doses (0.5 ml) given intramuscularly. WHO recommends an interval of 2–4 weeks between the first and second dose. It is recommended that all vaccinated individuals receive two doses.

If the second dose is administered less than 2 weeks after the first, the dose does not need to be repeated. If administration of the second dose is delayed beyond 4 weeks, it should be given at the earliest possible opportunity.


May 2021

COVID-19 Vaccines Advice

Posted by Juthatip


COVID-19 advice for the public: Getting vaccinated

Vaccines save millions of lives each year. Vaccines work by training and preparing the body’s natural defences – the immune system – to recognize and fight off the viruses and bacteria they target. After vaccination, if the body is later exposed to those disease-causing germs, the body is immediately ready to destroy them, preventing illness.


The COVID-19 vaccines are safe for most people 18 years and older, including those with pre-existing conditions of any kind, including auto-immune disorders. These conditions include: hypertension, diabetes, asthma, pulmonary, liver and kidney disease, as well as chronic infections that are stable and controlled.


  • Stay at the place where you get vaccinated for at least 15 minutes afterwards, just in case you have an unusual reaction, so health workers can help you.
  • Check when you should come in for a second dose – if needed. Most of the vaccines available are two-dose vaccines. Check with your care provider whether you need to get a second dose and when you should get it. Second doses help boost the immune response and strengthen immunity.
  • In most cases, minor side effects are normal. Common side effects after vaccination, which indicate that a person's body is building protection to COVID-19 infection include:
    • Arm soreness
    • Mild fever
    • Tiredness
    • Headaches
    • Muscle or joint aches


April 2021

Coronavirus variant tracker: Where different strains are spreading

Posted by Ratchaneewan

The coronavirus variants are being studied because they may be more transmissible, cause more severe disease, or reduce the efficacy of current vaccines.
No matter what strains of coronavirus, the best way to protect it is:

  • Wear a mask
  • Stay at least 6 feet apart
  • Avoid crowds

Variants of Concern

‘U.K. Variant’ B.1.1.7 ‘South Africa Variant’ B.1.351 ‘Brazil Variant’ P.1 ‘California Variants’ B.1.427/B.1.429
Transmissible 70% more transmissible 50% more transmissible Believed to be more transmissible, but more research needed 20% more transmissible
The ability to cause severe disease Up to 60% more deadly, but more research needed Unknown if it causes more severe disease Unknown if it causes more severe disease May cause more severe disease, but more research needed
Vaccine immunity ability Vaccines are still effective Some vaccines are less effective Vaccine efficacy is unknown Vaccines are likely still effective

Variants of Interest

‘New York Variants’ B.1.526/B.1.525 ‘Brazil Variant’ P.2
Transmissible Unknown if it is more or less transmissible Believed to be more transmissible, but more research needed
The ability to cause severe disease Unknown if it causes more severe disease Unknown if it causes more severe disease
Vaccine immunity ability Vaccine efficacy is unknown Vaccine efficacy is unknown


March 2021

Open Access

Posted by Ratchaneewan

Information on Open Access

What is Open Access?
Quoting from the website:
“Open access is a broad international movement that seeks to grant free and open online access to academic information, such as publications and data.
A publication is defined as 'open access' when there are no financial, legal, or technical barriers to accessing it - that is to say when anyone can read,
download, copy, distribute, print, search for and search within the information, or use it in education or in any other way within the legal agreements.”

Types of Open Access

Open Access content can also be classified based on the rights of authors:

  • Green Open Access: Content is fee-based but the publisher offers authors the ability to self-archive their work (pre-print or post-print) in Open Access repositories
  • Gold Open Access: Content is completely Open Access or open to all after an embargo period. The open content is offered on the publisher’s website.
  • Hybrid Open Access: Hybrid models of Open Access focuses on who will pay the cost of publishing Open Access materials and place the cost burden on the author,
    the institution, the library, or a combination by means of subscription credits, debits, or direct author payments.


Advantages of Open Access

Advantages of Open Access include :

  • Advantage 1. Free for all
  • Advantage 2. Increased readership
  • Advantage 3. Access for researchers in developing countries
  • Advantage 4. The ability of authors to retain full copyright of the article

For more information:

February 2021

Medical Encyclopedia

Posted by Juthatip



About MedlinePlus

  • MedlinePlus is an online health information resource for patients and their families and friends.
  • MedlinePlus is a service of the National Library of Medicine (NLM), the world's largest medical library, which is part of the National Institutes of Health (NIH).

The A.D.A.M. Medical Encyclopedia

The A.D.A.M. Medical Encyclopedia includes over 4,000 articles about diseases, tests, symptoms, injuries, and surgeries.
It also contains an extensive library of medical photographs and illustrations.
For more information about A.D.A.M., see its

  • Find encyclopedia articles A-Z
    The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition.
    A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions.
    Copyright 1997-2021 A.D.A.M., Inc. Duplication for commercial use must be authorized in writing by ADAM Health Solutions.


January 2021

The CGI faculty member ranked the World's Top 2% Scientists.

Posted by Ratchaneewan


Associate Professor Dr. Prasat Kittakoop ranked the World's Top 2% Scientists.

Associate Professor Dr. Prasat Kittakoop, a faculty member of the Chemical Sciences Program.
He is ranked as the world's top 2% most published and cited scientists (World Top 2% Scientists), according to a research team
led by Stanford University, Professor John PA Ioannidis.
The study was published in PLOS Biology Journal., the rankings were based on an analysis of research findings
which was based on research articles published in the SCOPUS database from 1996 to 2019 , using a variety of indicators.
For more information :

Associate Professor Dr. Prasat Kittakoop has 126 publications
and total citations of 3938 times with h-index (Scopus) = 38.
He is ranked as the World Top 2% Scientists in medicinal & biomolecular chemistry.
His research interests are natural products chemistry,
medicinal chemistry, and organic synthesis with green chemistry approach.
He published works in high impact factor journals, for example,
Angewandte Chemie International Edition (2019 Impact factor 12.959).

CGI Learning Center would like to thank Dr. Prasat for allowing this post on our web site.